（2025·江西·模拟预测）In recent years, China’s progress in artificial intelligence (AI) has drawn global attention.Meanwhile, a quieter yet equally significant transformation has been taking place in biotechnology.Traditionally known for producing common medicines and supplying raw materials, China has now emerged as a leader in innovative drug development. It is now the world’s second-largest source of new medicines, behind only the United States.
Some Western pharmaceutical companies (制药公司), which face potential losses of $140 billion annually because their drug patents are running out, are increasingly looking east for ideas. In 2023, nearly a third of major licensing deals were with Chinese firms, a threefold (三倍的) increase from 2020. According to LEK company, the total value of drugs licensed globally from China grew 15 - fold to $ 48 billion. Major pharmaceutical firms like Merck have secured licensing deals with Chinese biotech companies, such as LaNova Medicines, further demonstrating the industry’s growing appeal.
China’s biotech boom began seriously after official reforms in 2015. These changes reduced approval times for early-stage human testing from 501 to 87 days, and brought China in line with international standards. At the same time, the country benefited from returning scientists who had studied or worked abroad. A massive domestic market and relaxed listing regulations also fueled private investment, which rose sharply from $1 billion in 2016 to $13.4 billion in 2021.
Rather than simply producing generic drugs, Chinese firms have adopted a “fast-follower” approach, changing existing drugs to enhance safety, effectiveness, or delivery. This strategy has allowed for quicker and more cost-effective drug trials.
One area where Chinese companies have excelled (优于) is antibody-drug conjugates (ADCs), a promising cancer treatment. Since ADCs rely on existing components, success depends on optimizing their combination, an area where China has been very successful. Faster clinical trials provide another advantage. With a large patient population and government support, Chinese trials are often two to three times faster than those in the West. This efficiency has drawn interest from global pharmaceutical firms.
193．Why is China’s progress in AI mentioned?
A．To discuss AI’s global impact. B．To highlight China’s biotech rise.
C．To cite a major biotech breakthrough. D．To compare AI and biotech development.
194．What mainly drives Western companies to cooperate with China?
A．Huge losses from patent loss. B．Rapid growth of China’s drug market.
C．Faster drug approval process in China. D．Growing drug licensing deals with China.
195．What is paragraph 3 mainly about?
A．The contributions of returning scientists. B．The practice of biotech policy reforms.
C．The factors of China’s biotech development. D．The profit of increasing private investment.
196．What does “optimizing” in paragraph 5 most likely mean?
A．Improving. B．Adopting. C．Accelerating. D．Replacing.
【答案】193．B 194．A 195．C 196．A
【知识点】医疗 、社会问题与社会现象、说明文
该题有详细解析可以查阅1、本网站所提供的信息，只供教育教学参考之用。
2、本网站及其会员一概毋须以任何方式就任何信息传递或传送的失误、不准确或错误对用户或任何其他人士负任何直接或间接的责任。
3、在法律允许的范围内，本网站在此声明,不承担用户或任何人士就使用或未能使用本网站所提供的信息或任何链接或项目所引致的任何直接、间接、附带、从属、特殊、惩罚性或惩戒性的损害赔偿。
4、访问者在从事与本网站相关的所有行为(包括但不限于访问浏览、利用、转载、宣传介绍)时，必须以善意且谨慎的态度行事；访问者不得故意或者过失的损害本网站的各类合法权益，不得利用本网站以任何方式直接或者间接的从事违反中华人民共和国法律、国际公约以及社会公德的行为。对于访问者利用本网站提供的信息而作出的任何决策、决定以及其后果，本网站不承担任何责任
5、本网站图片，文字之类版权，本网站无法鉴别所上传图片或文字的知识版权，如果侵犯，请及时通知我们，本网站将在第一时间及时删除。
6、凡以任何方式登录本网站或直接、间接使用本网站资料者，视为自愿接受本网站声明的约束。
XueXi Design
